Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration ... - MarketWatch (press release)

Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration ...
MarketWatch (press release)
The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.
Myriad, Intermountain Healthcare Partner on MDx Evaluation GenomeWeb

all 10 news articles »

continue reading

Neighborhood Health Plan Launches Sleep Management Program - MarketWatch (press release)

Neighborhood Health Plan Launches Sleep Management Program
MarketWatch (press release)
SMS will provide utilization and network management services to enhance the overall quality of sleep services delivered, while also providing a cost-effective approach to diagnostic testing for NHP members. Through this partnership, SMS will use a ...

and more »

continue reading

Task force discourages use of prostate cancer screening test - Plain Dealer


Plain Dealer
Task force discourages use of prostate cancer screening test
Plain Dealer
For several years researchers at the Clinic and California-based Genomic Health have been working on a diagnostic test to determine whether a man's diagnosed prostate cancer should be treated right away or if it's a low-grade tumor that can be closely ...
All Routine PSA Tests For Prostate Cancer Should End, Task Force Says NPR (blog)
Medical journal reports that PSA screening tests for prostate cancer cause ... Straight.com

all 300 news articles »

continue reading

IVAX Diagnostics, Inc. Reports First Quarter 2012 Financial Results - MarketWatch (press release)

IVAX Diagnostics, Inc. Reports First Quarter 2012 Financial Results
MarketWatch (press release)
... manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (US), ...

and more »

continue reading

Hologic to buy diagnostic test maker Gen-Probe for $3.75 billion - Reuters


New York Times
Hologic to buy diagnostic test maker Gen-Probe for $3.75 billion
Reuters
O) said it would buy diagnostic test maker Gen-Probe Inc (GPRO.O) for about $3.75 billion in cash, gaining access to its chlamydia and gonorrhea tests and other blood screening products. The deal comes a year after Gen-Probe put itself up for sale and ...
Hologic to acquire Gen-Probe for about $3.72B in cash, expects deal to boost ... Washington Post
Hologic to buy Gen-Probe for about $3.72B The Associated Press
Hologic to buy Gen-Probe for $3.75 billion Baltimore Sun

all 319 news articles »

continue reading

Simple "head lag" test may help diagnose autism, research suggests - CBS News


eMaxHealth
Simple "head lag" test may help diagnose autism, research suggests
CBS News
A new study shows that a simple diagnostic test that checks how a child controls his or her head posture might provide another clue for pediatricians and parents. 10 early warning signs of autism Experimental drug reduces autism symptoms in mice, ...
Baby's poor head and neck control may be an autism clue ABC Action News
Lack of muscle development in infants: Could it predict autism? eMaxHealth
Your Baby's Head Movements Could Be a Sign of Autism The Stir

all 42 news articles »

continue reading

This Week In Diagnostics - OneMedPlace (blog)


OneMedPlace (blog)
This Week In Diagnostics
OneMedPlace (blog)
Quest Diagnostics says that it has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women. The new offerings feature a ...

continue reading

IRIS International Unveils NADiA(R) ProsVue(TM) at the American Urological ... - MarketWatch (press release)

IRIS International Unveils NADiA(R) ProsVue(TM) at the American Urological ...
MarketWatch (press release)
NADiA ProsVue is an in-vitro diagnostic assay for determining rate of change of serum total prostate specific antigen (tPSA) over a period of time. A retrospective clinical study of 304 patients evaluated the slope of three successive ProsVue tests ...

continue reading

Genetic Testing Has Not Resulted in Medical Overuse - PsychCentral.com


PsychCentral.com
Genetic Testing Has Not Resulted in Medical Overuse
PsychCentral.com
Genetic tests are available from a growing number of commercial producers. Health care providers and policymakers have been uncertain whether people who received information only about risk would follow up by demanding diagnostic testing to monitor for ...
Genetic Testing May Not Drive Up Health Costs MedPage Today

all 9 news articles »

continue reading

Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21(TM) PLUS Lab ... - MarketWatch (press release)

Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21(TM) PLUS Lab ...
MarketWatch (press release)
Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California.
Prenatal Diagnosis publishes Sequenom CMM's MaterniT21 PLUS LDT clinical study News-Medical.net

all 41 news articles »

continue reading